Cadence Capital Management’s Harvard Bioscience HBIO Stock Holding History

Cadence Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50,407	Closed	-$1.01M	–	439
2019 Q2	$1.01M	Sell	50,407 -1,688	-3%	-$49.5K	0.1%	278
2019 Q1	$2.25M	Buy	52,095 +911	+2%	+$33K	0.2%	154
2018 Q4	$1.63M	Buy	51,184 +15,944	+45%	+$628K	0.16%	190
2018 Q3	$1.85M	Buy	+35,240	New	+$1.98M	0.1%	280
2016 Q3	–	Sell	-27,381	Closed	-$783K	–	632
2016 Q2	$783K	Buy	27,381 +2,492	+10%	+$79.3K	0.06%	353
2016 Q1	$752K	Buy	24,889 +4,892	+24%	+$139K	0.05%	378
2015 Q4	$694K	Buy	19,997 +4,888	+32%	+$167K	0.05%	408
2015 Q3	$571K	Sell	15,109 -4,454	-23%	-$207K	0.04%	425
2015 Q2	$1.11M	Sell	19,563 -945	-5%	-$53.8K	0.06%	396
2015 Q1	$1.19M	Buy	20,508 +187	+0.9%	+$10K	0.07%	349
2014 Q4	$1.15M	Sell	20,321 -2,370	-10%	-$113K	0.07%	359
2014 Q3	$928K	Sell	22,691 -627	-3%	-$28.8K	0.05%	426
2014 Q2	$1.06M	Sell	23,318 -2,574	-10%	-$108K	0.05%	416
2014 Q1	$1.23M	Buy	25,892 +716	+3%	+$32.6K	0.05%	406
2013 Q4	$1.18M	Buy	25,176 +17,973	+250%	+$785K	0.04%	401
2013 Q3	$287K	Buy	+7,203	New	+$283K	0.01%	577

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Cadence Capital Management's HBIO Position: Q3 2019 in Review

Cadence Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2019, closing a stake of 50,407 shares — an estimated $1.01M sold.

Cadence Capital Management first reported a position in HBIO in Q3 2013 and held it in 16 quarters. The position peaked at $2.25M in Q1 2019. 71 funds tracked by Wall St. Rank hold HBIO as of Q3 2019.

Cadence Capital Management reported no remaining Harvard Bioscience position as of Q3 2019 after selling out during the quarter.
Cadence Capital Management sold 50,407 Harvard Bioscience shares in Q3 2019, an estimated $1.01M.
Cadence Capital Management first reported a position in Harvard Bioscience in Q3 2013 and held it in 16 quarters.
Cadence Capital Management's Harvard Bioscience position peaked at $2.25M in Q1 2019.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2019.

Based on Cadence Capital Management's 13F filing for Q3 2019, filed 29 Oct 2019.